Offer - Urjas Oil for just ₹ 1 X
Cabliz 0.25 Tablet is a commercial drug that is prescribed in the form of Tablet. It is primarily used for the treatment of Acromegaly, Prolactinoma.
The correct dosage of Cabliz 0.25 Tablet depends on the patient's age, gender, and medical history. The condition it has been prescribed for, and the route of administration also determine the right dosage. This information has been provided in detail in the dosage section.
While these are the most often observed Cabliz 0.25 Tablet side effects, there are can be others also. These have been listed below. These side effects of Cabliz 0.25 Tablet are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
It is also important to note that Cabliz 0.25 Tablet has a Mild effect for pregnant women and Severe effect on lactating mothers. It is important to know if Cabliz 0.25 Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Cabliz 0.25 Tablet related warnings section.
Cabliz 0.25 Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. High Blood Pressure, Heart Disease, Depression are examples of such conditions. Other conditions have been mentioned below in the Cabliz 0.25 Tablet contraindications section.
Besides this, Cabliz 0.25 Tablet may also have severe interaction with some medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Cabliz 0.25 Tablet is considered not safe while driving, and is not addictive.
Cabliz 0.25 Tablet is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Cabliz 0.25 Tablet safe for pregnant women?
Cabliz has little to no side effects in pregnant women.
Is the use of Cabliz 0.25 Tablet safe during breastfeeding?
Taking Cabliz may lead to serious side effects if you are breastfeeding. Cabliz should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Cabliz 0.25 Tablet on the Kidneys?
There may be some adverse effects on kidney after taking Cabliz. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Cabliz 0.25 Tablet on the Liver?
You may experience side effects on your liver after taking Cabliz. If this happens, then discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Cabliz 0.25 Tablet on the Heart?
Cabliz may cause harmful effects on the heart. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
If you are suffering from any of the following diseases, you should not take Cabliz 0.25 Tablet unless your doctor advises you to do so -
Is this Cabliz 0.25 Tablet habit forming or addictive?
Cabliz 0.25 Tablet is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Cabliz 0.25 Tablet as you may feel sleepy.
Is it safe?
Yes, but consume Cabliz 0.25 Tablet only on doctor's advice.
Is it able to treat mental disorders?
No, the use of Cabliz 0.25 Tablet in mental disorders is not effective.
Interaction between Food and Cabliz 0.25 Tablet
There is no information on the effects of taking Cabliz 0.25 Tablet with food, because this topic has not been scientifically researched yet.
Interaction between Alcohol and Cabliz 0.25 Tablet
Chances of side effects of drinking alcohol while taking Cabliz 0.25 Tablet are low. If you feel any adverse effects, please seek medical advice as soon as possible.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 174-176
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 239-240
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Dostinex® (cabergoline)